^
PD-L1 overexpression
Soft Tissue Sarcoma
camrelizumab
Sensitive: C4 – Case Studies
Front Oncol - 2 weeks
ETV6-NTRK3 fusion
Soft Tissue Sarcoma
larotrectinib
Sensitive: C4 – Case Studies
J Pediatr Hematol Oncol - 3 weeks
No biomarker
Soft Tissue Sarcoma
olaratumab
Sensitive: A1 - Approval
No biomarker
Soft Tissue Sarcoma
trabectedin
Sensitive: A1 - Approval
No biomarker
Soft Tissue Sarcoma
pazopanib
Sensitive: A1 - Approval
No biomarker
Soft Tissue Sarcoma
tazemetostat
Sensitive: A1 - Approval
No biomarker
Soft Tissue Sarcoma
doxorubicin hydrochloride
Sensitive: A1 - Approval
No biomarker
Soft Tissue Sarcoma
ifosfamide + epirubicin + mesna
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
AIM
Sensitive: A2 - Guideline
NTRK3 fusion
Soft Tissue Sarcoma
entrectinib
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
GT
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
ifosfamide
Sensitive: A2 - Guideline
NTRK1 fusion
Soft Tissue Sarcoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Soft Tissue Sarcoma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Soft Tissue Sarcoma
larotrectinib
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
gemcitabine + dacarbazine
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
cediranib
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
sunitinib
Sensitive: A2 - Guideline
ALK translocation
Soft Tissue Sarcoma
crizotinib
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
regorafenib
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
ifosfamide + pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
temozolomide
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
dacarbazine
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
gemcitabine + vinorelbine tartrate
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
MAID
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
epirubicin
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
Tyrosine kinase inhibitor
Sensitive: A2 - Guideline
NTRK1 fusion
Soft Tissue Sarcoma
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Soft Tissue Sarcoma
entrectinib
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
eribulin mesylate
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
gemcitabine + docetaxel
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
doxorubicin hydrochloride + ifosfamide + mesna
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
AD
Sensitive: A2 - Guideline
ALK translocation
Soft Tissue Sarcoma
brigatinib
Sensitive: A2 - Guideline
ALK translocation
Soft Tissue Sarcoma
ceritinib
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
bevacizumab
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
sorafenib
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
vinorelbine
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
No biomarker
Soft Tissue Sarcoma
SA033
Sensitive: A2 - Guideline
MSH3 overexpression
Soft Tissue Sarcoma
ifosfamide + epirubicin
Resistant: B - Late Trials
No biomarker
Soft Tissue Sarcoma
L-ANN
Sensitive: B - Late Trials
PD-L1 expression
Soft Tissue Sarcoma
nivolumab + ipilimumab
Sensitive: C1 - Off-label
KIAA1549-BRAF fusion
Soft Tissue Sarcoma
bevacizumab + sorafenib + temsirolimus
Sensitive: C3 – Early Trials
CUL4A overexpression
Soft Tissue Sarcoma
trabectedin
Sensitive: C3 – Early Trials
ERCC5 overexpression
Soft Tissue Sarcoma
trabectedin
Sensitive: C3 – Early Trials
ERCC1 overexpression
Soft Tissue Sarcoma
trabectedin
Sensitive: C3 – Early Trials
TAF15-NR4A3 fusion
Soft Tissue Sarcoma
sunitinib
Resistant: C3 – Early Trials
EWSR1-NR4A3 fusion
Soft Tissue Sarcoma
sunitinib
Sensitive: C3 – Early Trials
SMARCB1 deletion
Soft Tissue Sarcoma
tazemetostat
Sensitive: C3 – Early Trials
SS18-SSX fusion
Soft Tissue Sarcoma
venetoclax + S63845
Sensitive: C3 – Early Trials
IFIH1 expression
Soft Tissue Sarcoma
Immunotherapy
Sensitive: C3 – Early Trials
CTSG expression
Soft Tissue Sarcoma
Immunotherapy
Sensitive: C3 – Early Trials
STC2 expression
Soft Tissue Sarcoma
Immunotherapy
Sensitive: C3 – Early Trials
SECTM1 expression
Soft Tissue Sarcoma
Immunotherapy
Sensitive: C3 – Early Trials
LAG3 overexpression
Soft Tissue Sarcoma
trabectedin
Sensitive: C3 – Early Trials
CTLA4 overexpression
Soft Tissue Sarcoma
trabectedin
Sensitive: C3 – Early Trials
PD-L1 expression
Soft Tissue Sarcoma
trabectedin
Sensitive: C3 – Early Trials
CDK4 amplification
Soft Tissue Sarcoma
palbociclib
Sensitive: C3 – Early Trials
RB1 expression
Soft Tissue Sarcoma
palbociclib
Sensitive: C3 – Early Trials
TFE3 rearrangement + MET expression
Soft Tissue Sarcoma
crizotinib
Sensitive: C3 – Early Trials
HMGA1 overexpression
Soft Tissue Sarcoma
trabectedin
Resistant: C3 – Early Trials
HDAC1 amplification
Soft Tissue Sarcoma
PD1 inhibitor + chidamide
Sensitive: C3 – Early Trials
PD-L1 expression
Soft Tissue Sarcoma
pazopanib
Resistant: C3 – Early Trials
CLDN6 positive
Soft Tissue Sarcoma
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
DDR
Soft Tissue Sarcoma
olaparib
Sensitive: C3 – Early Trials
MAD2L2 underexpression
Soft Tissue Sarcoma
olaparib + trabectedin
Sensitive: C3 – Early Trials
XRCC2 underexpression
Soft Tissue Sarcoma
olaparib + trabectedin
Sensitive: C3 – Early Trials
RAD54L underexpression
Soft Tissue Sarcoma
olaparib + trabectedin
Sensitive: C3 – Early Trials
BLM underexpression
Soft Tissue Sarcoma
olaparib + trabectedin
Sensitive: C3 – Early Trials
APEX2 underexpression
Soft Tissue Sarcoma
olaparib + trabectedin
Sensitive: C3 – Early Trials
ATM overexpression
Soft Tissue Sarcoma
olaparib + trabectedin
Sensitive: C3 – Early Trials
SLFN11 overexpression
Soft Tissue Sarcoma
olaparib + trabectedin
Sensitive: C3 – Early Trials
PIK3R1 overexpression
Soft Tissue Sarcoma
olaparib + trabectedin
Sensitive: C3 – Early Trials
CDKN2A overexpression
Soft Tissue Sarcoma
olaparib + trabectedin
Sensitive: C3 – Early Trials
COL1A1-PDGFB fusion
Soft Tissue Sarcoma
imatinib
Sensitive: C3 – Early Trials
KANK1-NTRK2 fusion
Soft Tissue Sarcoma
crizotinib
Sensitive: C3 – Early Trials
ERC1-ALK fusion
Soft Tissue Sarcoma
crizotinib
Sensitive: C3 – Early Trials
LMNA-NTRK1 fusion
Soft Tissue Sarcoma
larotrectinib
Sensitive: C4 – Case Studies
RANBP2-ALK fusion
Soft Tissue Sarcoma
doxorubicin hydrochloride
Resistant: C4 – Case Studies
RANBP2-ALK fusion
Soft Tissue Sarcoma
crizotinib
Sensitive: C4 – Case Studies
ATF1 overexpression
Soft Tissue Sarcoma
ruxolitinib
Sensitive: C4 – Case Studies
PDE4DIP-NTRK1 fusion
Soft Tissue Sarcoma
doxorubicin hydrochloride + ifosfamide
Resistant: C4 – Case Studies
YWHAE-ROS1 fusion
Soft Tissue Sarcoma
crizotinib
Sensitive: C4 – Case Studies
SQSTM1-NTRK1 fusion
Soft Tissue Sarcoma
larotrectinib
Sensitive: C4 – Case Studies
PDE4DIP-NTRK1 fusion
Soft Tissue Sarcoma
larotrectinib
Sensitive: C4 – Case Studies
JAK1 overexpression
Soft Tissue Sarcoma
ruxolitinib
Sensitive: C4 – Case Studies
PIK3CA E542K
Soft Tissue Sarcoma
trametinib + pazopanib
Sensitive: C4 – Case Studies
DCTN1-NTRK1 fusion
Soft Tissue Sarcoma
BAY 2731954
Resistant: C4 – Case Studies
DCTN1-NTRK1 fusion
Soft Tissue Sarcoma
larotrectinib
Resistant: C4 – Case Studies
STRN-NTRK2 fusion + CDKN2B Deletion
Soft Tissue Sarcoma
larotrectinib
Sensitive: C4 – Case Studies
PD-L1 expression
Soft Tissue Sarcoma
camrelizumab
Sensitive: C4 – Case Studies